These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33710976)

  • 1. Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age.
    Arrieta AC; Ang JY; Espinosa C; Fofanov O; Tøndel C; Chou MZ; De Anda CS; Kim JY; Li D; Sabato P; Sears PS; Bradley JS
    Pediatr Infect Dis J; 2021 Apr; 40(4):317-323. PubMed ID: 33710976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents.
    Bradley JS; Flanagan SD; Arrieta AC; Jacobs R; Capparelli E; Prokocimer P
    Pediatr Infect Dis J; 2016 Jun; 35(6):628-33. PubMed ID: 26910588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects.
    Kim Y; Kim A; Lee S; Choi SH; Lee DY; Song JS; Lee H; Jang IJ; Yu KS
    Clin Ther; 2017 Sep; 39(9):1849-1857. PubMed ID: 28865799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Safety of Tedizolid after Single and Multiple Intravenous/Oral Sequential Administrations in Healthy Chinese Subjects.
    Chen R; Shen K; Chang X; Tanaka T; Li L; Hu P
    Clin Ther; 2016 Aug; 38(8):1869-79. PubMed ID: 27461846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid.
    Flanagan S; Fang E; Muñoz KA; Minassian SL; Prokocimer PG
    Pharmacotherapy; 2014 Sep; 34(9):891-900. PubMed ID: 24989138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate in Elderly Subjects.
    Flanagan SD; Minassian SL; Prokocimer P
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):788-794. PubMed ID: 29319932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - Results of a randomised, multicentre phase 3 study.
    Mikamo H; Takesue Y; Iwamoto Y; Tanigawa T; Kato M; Tanimura Y; Kohno S
    J Infect Chemother; 2018 Jun; 24(6):434-442. PubMed ID: 29530544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
    Prokocimer P; De Anda C; Fang E; Mehra P; Das A
    JAMA; 2013 Feb; 309(6):559-69. PubMed ID: 23403680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections.
    Urbina O; Ferrández O; Espona M; Salas E; Ferrández I; Grau S
    Drug Des Devel Ther; 2013; 7():243-65. PubMed ID: 23589680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug.
    Flanagan SD; Bien PA; Muñoz KA; Minassian SL; Prokocimer PG
    Pharmacotherapy; 2014 Mar; 34(3):240-50. PubMed ID: 23926058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.
    Flanagan S; Minassian SL; Morris D; Ponnuraj R; Marbury TC; Alcorn HW; Fang E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6471-6. PubMed ID: 25136024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections.
    Ortiz-Covarrubias A; Fang E; Prokocimer PG; Flanagan SD; Zhu X; Cabré-Márquez JF; Tanaka T; Passarell J; Fiedler-Kelly J; Nannini EC
    Braz J Infect Dis; 2016; 20(2):184-92. PubMed ID: 26859064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.
    McBride D; Krekel T; Hsueh K; Durkin MJ
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):331-337. PubMed ID: 28140693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections.
    Bradley JS; Antadze T; Ninov B; Tayob MS; Broyde N; Butterton JR; Chou MZ; De Anda CS; Kim JY; Sears PS
    Pediatr Infect Dis J; 2021 Mar; 40(3):238-244. PubMed ID: 33395210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis.
    Park AYJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary.
    O'Riordan W; Green S; Mehra P; De Anda C; Fang E; Prokocimer P
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S43-50. PubMed ID: 24343832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.
    Ong V; Flanagan S; Fang E; Dreskin HJ; Locke JB; Bartizal K; Prokocimer P
    Drug Metab Dispos; 2014 Aug; 42(8):1275-84. PubMed ID: 24875463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.
    Douros A; Grabowski K; Stahlmann R
    Expert Opin Drug Metab Toxicol; 2015; 11(12):1849-59. PubMed ID: 26457865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
    Moran GJ; Fang E; Corey GR; Das AF; De Anda C; Prokocimer P
    Lancet Infect Dis; 2014 Aug; 14(8):696-705. PubMed ID: 24909499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.